Timing of Minimally Invasive Local Treatment After First-Line Systemic Therapy in Oligometastatic Esophageal or Gastric Adenocarcinoma

Purpose of the Study: This clinical study investigates whether a shorter or longer duration of systemic therapy before local treatment (surgery or radiation) results in better disease control in patients with esophageal or gastric cancer with a limited number of metastases, also known as oligometastases. Background: In about 25% of patients with advanced esophageal or gastric cancer, the disease spreads to only a few sites (oligometastatic disease). Prior studies suggest that local treatment after systemic therapy may extend survival in this subgroup. However, it is unclear how long systemi

Trial Details

NCT ID
NCT07000253
Phase
PHASE2 / PHASE3
Sponsor
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Status
RECRUITING
Cancer Type
Adenocarcinoma Esophageal Cancer
Interventions
  • Chemotherapy
  • Targeted Systemic Therapy
  • Immunotherapy
  • Surgery
  • Radiotherapy
Locations (sample)
  • Amsterdam, Netherlands|52.37403,4.88969
  • Utrecht, Netherlands|52.09083,5.12222

Key Eligibility Criteria

  • Age ≥18 years
  • Ability to provide written informed consent
  • Histologically confirmed esophageal, gastric or gastroesophageal junction tumor with oligometastatic (M1) disease defined according to the OMEC con…
  • One organ with ≤3 metastases or 1 involved extra-regional lymph node station (based on the TNM 8 classification)

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Adenocarcinoma Esophageal Cancer Trials on Trialify →